A pilot trial of human amniotic fluid for the treatment of COVID-19

BMC Research Notes

Table 2 Outcomes of 10 enrolled patients

Patient	Admit	Initial O2	Maximum O2	Co-Rx	CRP	IL-6	D-dimer	LDH	Discharge
1	ICU	ETT	ECMO/Trach	HCQ,	+ 30%	+ 38%	+ 138%	− 27%	Alive
2	Floor	NC	NC	HCQ	N/A	N/A	N/A	− 28%	Alive
3	Floor	NC	ETT	HCQ, Rem	N/A	N/A	N/A	− 20%	Deceased
4	ICU	NC	NC	HCQ	N/A	N/A	N/A	N/A	Alive
5	ICU	ETT	ETT	HCQ	− 84%	− 60%	− 21%	− 22%	Alive
6	ICU	ETT	Trach	HCQ-AZ	− 91%	0	− 42%	N/A	Alive
7	ICU	HFNC	HFNC	HCQ	+ 46%	+ 109%	+ 818%	+ 109%	Alive
8	ICU	NC	HFNC	AZ	− 87%	0	0	− 21%	Alive
9	ICU	NC	Simple mask	HCQ	− 80%	− 20%	− 28%	+ 109%	Alive
10	ICU	HFNC	ETT	HCQ	+ 41%	+ 412%	+ 33%	− 30%	Alive

Of note, protocol change (10 cc hAF I.V.) for patients 5–10. N/A not available, ECMO extracorporeal membrane oxygenation, ETT endotracheal intubation, HFNC high flow nasal cannula, ICU intensive care unit, MACE major adverse cardiac event, NC nasal cannula, O2 oxygen, Trach tracheostomy, Co-Rx Co-treatment, HCQ hydroxychloroquine, AZ azithromycin; Rem remdesivir. Biomarker are represented as a percent change between study enrollment and termination of hAF (5 days) with focus on the last 6 patients under current protocol. CRP: C-reactive protein; IL-6: interleukin-6; LDH: lactate dehydrogenase

ISSN: 1756-0500